103,517 Shares in Astria Therapeutics, Inc. $ATXS Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired 103,517 shares of Astria Therapeutics, Inc. valued at approximately $553,000, representing 0.18% of the company.
• A number of hedge funds, including Hsbc Holdings PLC and Tower Research Capital LLC, have recently increased their positions in Astria Therapeutics during the 4th quarter.
• Analysts have a generally positive outlook on Astria Therapeutics, with an average rating of "Buy" and a target price of $29.00.

Nuveen LLC purchased a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 103,517 shares of the biotechnology company's stock, valued at approximately $553,000. Nuveen LLC owned 0.18% of Astria Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Astria Therapeutics during the fourth quarter valued at about $50,000. GAMMA Investing LLC raised its stake in shares of Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 7,971 shares during the last quarter. Corton Capital Inc. bought a new position in shares of Astria Therapeutics during the first quarter valued at about $72,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Astria Therapeutics during the fourth quarter valued at about $137,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Stock Down 0.4%

Shares of NASDAQ ATXS traded down $0.03 on Tuesday, reaching $7.40. 61,724 shares of the company's stock traded hands, compared to its average volume of 353,900. The business's 50 day simple moving average is $6.54 and its two-hundred day simple moving average is $5.68. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92. The company has a market cap of $417.66 million, a price-to-earnings ratio of -3.66 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. Analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ATXS. JMP Securities upped their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 13th. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $47.00 price target on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.